Core Viewpoint - Tianyu Co., Ltd. focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to deepen its "customer first" strategic goal [1] Group 1: Business Strategy - The company has provided active pharmaceutical ingredients (APIs) for 8 original research drug varieties and aims to add 1-2 new commercialized APIs annually with original research drug companies [1] - The company seeks to strengthen existing partnerships with original research clients while expanding its customer base to enhance its competitive advantage in APIs [1] Group 2: Strategic Partnerships - Tianyu has established long-term stable strategic partnerships with internationally renowned pharmaceutical companies such as Novartis, Sanofi, and Daiichi Sankyo [1] - The scope of cooperation has expanded from sartans APIs to non-sartan APIs, off-patent drugs, and innovative drug CDMO projects, indicating an increase in both depth and breadth of collaboration [1]

Group 1: R&D and Client Collaboration - The company focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to provide raw materials for 8 original drug varieties and plans to add 1-2 new commercialized raw materials annually [2] - Established long-term strategic partnerships with renowned pharmaceutical companies such as Novartis and Sanofi, expanding collaboration from sartan raw materials to non-sartan raw materials, patent-expired drugs, and innovative drug projects [2] Group 2: CDMO Business Strategy - The company has built a solid service foundation and professional competitiveness in the generic drug raw material field, leveraging a comprehensive GMP system and compliance capabilities [3] - The CDMO business focuses on strategic clients, prioritizing high-potential projects during patent periods and late-stage development, ensuring significant scale benefits and customer loyalty [3] Group 3: Business Growth Outlook for 2026 - Raw material segment: Sartan raw materials' revenue share is expected to decline, while non-sartan raw materials (e.g., sitagliptin, ezetimibe) are projected to be core growth drivers, maintaining rapid growth and potential margin improvement [4] - CDMO business: Revenue may face pressure due to changing client demands, but the company is actively pursuing new project opportunities to maintain stability [4] - Formulation business: Expected to continue rapid growth due to expanding market channels, despite a small revenue base [4] - Acetonitrile project: The annual production capacity of 20,000 tons has passed acceptance in January 2026, targeting high-end fields such as peptides and small nucleic acids [4] Group 4: Profitability and Cost Management - Sartan raw materials maintain a gross margin above 30% despite competitive pricing pressures, with expectations for stable margins as prices stabilize [5] - Non-sartan raw materials' gross margin is expected to improve as production increases and costs decrease, aiming to align closer to sartan products [5] Group 5: R&D and Sales Expenses - The company's overall R&D investment will remain stable at approximately 2.5-2.8 billion annually, with a rising proportion allocated to raw materials and CDMO R&D [5] - Sales expenses are increasing rapidly in the formulation business due to its growth, with the company enhancing marketing control through digital systems [5]

Core Viewpoint - The company, Baillie Tianheng, is expected to report a net profit of -1.1 billion CNY for 2025, marking a significant decline of 129.67% year-on-year, reflecting the challenges faced by Chinese innovative pharmaceutical companies in balancing R&D investment and commercialization [2][29]. Financial Performance - Baillie Tianheng's revenue for 2025 is projected to be approximately 2.5 billion CNY, a decrease of 33.23 billion CNY or 57.06% compared to the previous year [2][29]. - The company has reported consecutive losses from 2021 to 2023, accumulating losses of 1.3 billion CNY [5][31]. - In 2024, the company achieved a revenue of 5.823 billion CNY and a net profit of 3.708 billion CNY, a staggering increase of 575.02% year-on-year, primarily driven by an 800 million USD upfront payment from BMS [5][31]. R&D Investment - The company has significantly increased its R&D investment, with a reported expenditure of 1.772 billion CNY in the first three quarters of 2025, a 90.23% increase year-on-year, accounting for 85.79% of its operating revenue [5][31]. - The company has 17 innovative drugs in clinical trials, with over 100 ongoing clinical trials globally, including more than 90 in China [21][48]. IPO and Market Performance - Baillie Tianheng's plans for an IPO in Hong Kong have faced delays, with the company announcing a postponement of its global offering due to current market conditions [9][36]. - The company had initially planned to issue 8.6343 million H-shares, aiming to raise approximately 3.359 billion HKD [10][37]. Product Pipeline and Commercialization - The core product, BL-B01D1, is a dual-target ADC drug that has completed Phase III clinical trials and aims to treat various cancers [17][44]. - The potential annual peak sales for BL-B01D1 are estimated to reach 20 billion USD, but the product has yet to achieve commercialization [23][50]. - The company is currently facing challenges in its commercialization capabilities, as it has no marketed innovative drug products and its traditional business continues to decline [24][50]. Conclusion - The performance fluctuations of Baillie Tianheng highlight the pitfalls of relying on one-time revenue models in the innovative pharmaceutical sector, emphasizing the need for effective commercialization of R&D investments [25][51]. - The company's future success will depend on its ability to balance R&D investments with sustainable revenue generation and the successful commercialization of its core products [52].

Core Viewpoint - Merck's (MRK.US) latest quarterly performance report and future outlook fell short of market expectations, primarily due to challenges faced by its HPV vaccine Gardasil, which is expected to struggle in the Chinese market, overshadowing strong growth from other products like Keytruda and new drugs [1][2]. Financial Performance - In Q4, Merck reported total sales of approximately $16.4 billion, a 5% year-over-year increase, exceeding analyst expectations of about $16.2 billion [2]. - Non-GAAP net profit for the quarter was approximately $5.088 billion, reflecting a 16% year-over-year growth, with adjusted earnings per share at $2.04, slightly above analyst forecasts [2]. - Gardasil's sales in Q4 were approximately $1.03 billion, down about 35% year-over-year, attributed to global economic uncertainties and competitive pressures [3]. Product Challenges - Gardasil is facing significant challenges in both the Chinese market, where demand has sharply declined, and in the U.S., where health officials have recommended reducing vaccination doses [2][3]. - Merck has paused Gardasil shipments to China until the end of 2025, not factoring any shipments in its 2026 guidance [1]. Growth Opportunities - Despite Gardasil's challenges, Merck is experiencing growth in other areas, including a new pneumonia vaccine and the rare disease drug Winrevair, which saw a 133% increase in Q4 sales [4]. - Winrevair achieved sales of approximately $467 million in Q4, exceeding analyst expectations [4]. Strategic Initiatives - Merck is preparing for potential price reductions and competition for its top-selling cancer drug Keytruda, which faces patent expiration in 2028 [5][6]. - The company is actively seeking significant acquisition opportunities, with CEO Robert Davis indicating a focus on strategic acquisitions to bolster its drug pipeline [6][8]. Future Outlook - Merck's management is prioritizing oncology treatment innovations and plans to diversify its cancer product line beyond Keytruda [8][9]. - The company is exploring new mechanisms in immunotherapy and potential acquisitions in chronic disease treatments, particularly in COPD and metabolic disorders [9].

Financial Performance - In Q3 2026, Daiichi Sankyo reported a revenue increase of 15.1% year-on-year to ¥558 billion, and a net profit increase of 39.9% to ¥87 billion, both exceeding Bloomberg consensus expectations[5] - Sales of Enhertu grew by 31.7% year-on-year to ¥188 billion, driven by its recent approval for first-line treatment of breast cancer[5] - Datroway sales increased by 52.9% quarter-on-quarter to ¥15.9 billion, prompting management to raise the full-year sales guidance for Datroway from ¥37.8 billion to ¥47 billion[5] Key Developments - The release of key data from four major Phase III trials for Datroway has been postponed, with the Avanzar trial results now expected in the second half of 2026[6] - The company is shifting towards biomarker-driven research, as evidenced by the recent launch of the Tropion-Lung17 trial, which uses TROP2 standardized membrane ratio (NMR) for patient selection[6] Risks and Challenges - Despite the efficacy of drugs like Enhertu, toxicity concerns remain, with potential FDA black box warnings limiting its use in broader patient populations[8] - The reliance on a few key products like Enhertu may pose long-term risks if clinical or regulatory outcomes do not meet market expectations[8] - The COVID-19 pandemic may impact sales due to patients avoiding hospitals, affecting the penetration of new products[9]

评级：中性(维持) 曹泽运(证券分析师) 李畅(证券分析师) S0350525110001 S0350524010004 caozy@ghzq.com.cn lic05@ghzq.com.cn 证券研究报告 2026年01月30日 医药生物 生物医药深度报告：国产ADC药物即将迎来高光时刻 ——ADC子行业专题研究 最近一年走势 相关报告 《医药生物行业动态研究：中国独立医学实验室行业的先行者（中性）*医药生 物*曹泽运，林羽茜》——2026-01-27 《医药生物行业动态研究：AI药研或引产业革命，JPM大会再推行业新峰（中 性）*医药生物*曹泽运，林羽茜》——2026-01-20 相对沪深300表现 | 表现 | 1M | 3M | 12M | | --- | --- | --- | --- | | 医药生物 | 2.0% | -2.7% | 21.1% | | 沪深300 | 2.1% | 1.3% | 24.5% | 请务必阅读报告附注中的风险提示和免责声明 2 -9% 0% 9% 19% 28% 37% 2025/02/05 2025/05/06 2025/08/04 2025/11/02 医药生物 ...

MACD金叉信号形成，这些股涨势不错！ 日本股市可能下跌，此前华尔街科技股隔夜遭抛售。日经指数期货在新加坡交易所下跌0.2%，报53， 220点。美元兑日元报152.98日元，周四东京股市收盘时为152.96日元。投资者正在关注财报，第一三 共、豪雅和小松制作所将公布业绩。首相高市早苗的经济计划也备受关注，下月初将举行大选。日经指 数周四收盘持平于53，375.60点。 MACD金叉信号形成，这些股涨势不错！ 日本股市可能下跌，此前华尔街科技股隔夜遭抛售。日经指数期货在新加坡交易所下跌0.2%，报53， 220点。美元兑日元报152.98日元，周四东京股市收盘时为152.96日元。投资者正在关注财报，第一三 共、豪雅和小松制作所将公布业绩。首相高市早苗的经济计划也备受关注，下月初将举行大选。日经指 数周四收盘持平于53，375.60点。 责任编辑：王永生 责任编辑：王永生 ...

Core Insights - The article highlights the inclusion of Ivonescimab, a PD-1/VEGF bispecific antibody developed by Kangfang Biopharma, in the FirstWord Pharma's "Spotlight On: The drugs that will shape 2026" list, marking it as the only drug from a Chinese innovative pharmaceutical company [1][2] Company Overview - Kangfang Biopharma, established in 2012 in Zhongshan, focuses on addressing unmet clinical needs through technological innovation and has developed over 50 innovative drug candidates targeting major diseases [4] - The company is the only pharmaceutical firm globally with two tumor immune bispecific antibody drugs, with seven new drugs already commercialized and four additional indications under review [4] Drug Development and Market Potential - Ivonescimab is set to receive approval from the National Medical Products Administration of China in May 2024 for treating locally advanced or metastatic non-small cell lung cancer (nsq-NSCLC) after progression on EGFR-TKI therapy [2] - The drug has been recognized for its clinical value and commercial potential, being included in the national medical insurance catalog in November 2024 [2] - The global development of Ivonescimab, in collaboration with Summit Therapeutics, positions it as a leader in the PD-(L)1/VEGF bispecific antibody space, with significant attention on its potential in broader clinical applications beyond second-line NSCLC [3] Industry Context - The trend of developing PD-(L)1/VEGF bispecific antibodies is largely driven by China, with clinical studies indicating enhanced efficacy in treating non-small cell lung cancer compared to PD-1 monotherapy [3] - The biopharmaceutical industry in Zhongshan is recognized as a key sector, with the city expanding its health base and establishing a comprehensive support system for biopharmaceutical innovation, including a 10 billion yuan angel fund [4][5]

图片来源：GETTY 韩国Sam Chun Dang Pharm（SCD）宣布与日本制药公司第一三共（Daiichi Sankyo）合作，联合研发并商业化一款减肥口服药。消息一出，这 家韩国公司股价大涨，董事长尹大仁（Yoon Dae-in）也借此跻身亿万富豪之列。 投资者对SCD正在开发的减肥口服药（减肥针剂的口服剂型）持乐观态度，受此提振，公司股价本月迄今涨幅超75%。此次股价暴涨，也让公司董事长尹 大仁成功跻身亿万富豪行列。 SCD研发的另一项创新给药系统是基于微球技术的长效注射剂，这种注射剂通过注入定时释放的微型药丸，使药物在数月内缓慢释放。1月7日，SCD宣布 签署一项潜在价值高达20亿美元的协议，获得在美国独家销售亮丙瑞林长效注射剂版本的权利。亮丙瑞林是日本武田制药（Takeda）研发的激素类药物， 主要用于治疗前列腺癌。该长效注射版本由SCD基于其微球缓释技术自主开发。根据协议，SCD将获得约1亿美元的首付款及里程碑付款，其余款项则通 过双方各占50%的利润分成机制实现。 2025年前九个月，SCD营收同比增长6.3%，达1655亿韩元（约合1.13亿美元）。同期，净利润同比大增76%，升至70 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [3] Core Insights - The recent policy released by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical retail sector is anticipated to see improved performance expectations due to favorable policies, with a recommendation to focus on quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin [6][33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Year-to-date, the pharmaceutical and biotechnology index has increased by 6.66%, outperforming the CSI 300 index by 5.1 percentage points, ranking 16th [11] - The best-performing sub-sector this week was pharmaceutical commerce, which rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] Stock Performance - Among 478 pharmaceutical and biotechnology stocks, 338 stocks increased, representing 70.71% of the total [22] - The top five A-share stocks by performance this week were: *ST Changyao (+70.37%), Hualan Biological Engineering (+32.21%), Kangzhong Medical (+25.47%), Hanshang Group (+20.06%), and Wanze Shares (+19.04%) [22] - In the Hong Kong market, 116 pharmaceutical and biotechnology stocks saw 32 stocks rise, accounting for 27.59% [25] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and optimize industry structure [28] - The FDA granted fast-track designation to CM336, a dual antibody developed by Kangnuo, for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia [31] Recommendations - The report suggests focusing on quality pharmacy enterprises in light of the favorable policies for the pharmaceutical retail sector [33] - It also highlights the potential for vaccine companies in response to the recent Nipah virus cases in India, recommending attention to companies like Zhifei Biological, Kangtai Biological, Watson Bio, and CanSino [34]